Venous Thromboembolism in Sickle Cell Disease is Associated with Neutrophilia

被引：8

作者：

Gollamudi, Jahnavi ^{[1
]}

Sarvepalli, Shashank ^{[2
]}

Vadaparti Binf, Animesh ^{[3
]}

Alin, Tara ^{[4
,5
]}

Little, Jane A. ^{[4
,5
]}

Nayak, Lalitha ^{[6
]}

机构：

[1] Baylor Coll Med, Dept Internal Med, Div Hematol Oncol, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Internal Med, Div Gastroenterol, Houston, TX 77030 USA

[3] Guelph Univ, Dept Integrat Biol, Guelph, ON, Canada

[4] Univ N Carolina, Div Hematol, Chapel Hill, NC 27515 USA

[5] Univ N Carolina, UNC Blood Res Ctr, Dept Internal Med, Chapel Hill, NC 27515 USA

[6] Seidman Canc Ctr, Dept Internal Med, Div Hematol Oncol, Cleveland, OH USA

来源：

HEMOGLOBIN | 2021年 / 45卷 / 01期

关键词：

Leukocytosis; neutrophilia; predictors; sickle cell disease; venous thromboembolism (VTE);

D O I：

10.1080/03630269.2020.1869565

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Venous thromboembolism (VTE) in individuals with sickle cell disease is common and portends a poor prognosis. The role of leukocyte count and its subsets on risk of VTE in sickle cell disease are not known. We conducted a retrospective case-control study and analyzed for leukocyte count at the time of VTE and 3 months prior. Leukocyte and neutrophil counts were elevated at the time of VTE (p = 0.003 and p = 0.0006, respectively) and 3 months prior (p = 0.001 and p = 0.0096, respectively) when compared to controls. Baseline leukocytosis and neutrophilia may be associated with subsequent risk for thrombosis in sickle cell disease.

引用

页码：56 / 59

页数：4

共 50 条

[31] Venous thromboembolism in adults with sickle cell disease: experience of a single centre in the UK
V. van Hamel Parsons
K Gardner
R Patel
S L Thein
Annals of Hematology, 2016, 95 : 227 - 232
[32] The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease
Gupta, Vishal K.
Lawrence, Romy Carmen
Khan, Sarah L.
Strykowski, Rachel
Scarpato, Brittany
Cohen, Robyn T.
Sloan, John Mark
Klings, Elizabeth S.
BLOOD, 2019, 134
[33] Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease
Denise Kelley
Lauren Thornton Jones
Jun Wu
Nicole Bohm
Journal of Thrombosis and Thrombolysis, 2017, 43 : 463 - 468
[34] COVID-19 and venous thromboembolism risk in patients with sickle cell disease
Singh, Ashima
Brandow, Amanda M.
Wun, Ted
Shet, Arun S.
BLOOD ADVANCES, 2022, 6 (15) : 4408 - 4412
[35] Sickle Cell Disease and Venous Thromboembolism: Hospital Mortality, Length of Stay and Cost
Rainone, Michael
Perimbeti, Stuthi Pavani
Shrivastav, Rishi
Glassberg, Jeffrey A.
Cytryn, Lawrence
BLOOD, 2018, 132
[36] Venous thromboembolism in adults with sickle cell disease: experience of a single centre in the UK
Parsons, V. van Hamel
Gardner, K.
Patel, R.
Thein, S. L.
ANNALS OF HEMATOLOGY, 2016, 95 (02) : 227 - 232
[37] A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation
Di Maggio, Rosario
Giuliano, Alessandra
Renda, Disma
Calvaruso, Giuseppina
Raso, Simona
Pitrolo, Lorella
Carroccio, Antonio
Maggio, Aurelio
THALASSEMIA REPORTS, 2022, 12 (03) : 85 - 89
[38] Venous Thromboembolism Incidence In The Cooperative Study Of Sickle Cell Disease: The Untold Story
Naik, Rakhi P.
Haywood, Carlton, Jr.
Streiff, Michael B.
Lanzkron, Sophie
BLOOD, 2013, 122 (21)
[39] Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know
Naik, Rakhi P.
Streiff, Michael B.
Lanzkron, Sophie
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 35 (03) : 352 - 358
[40] Enoxaparin adherence for venous thromboembolism prophylaxis in hospitalized patients with sickle cell disease
Sakon, Colleen
Nikirk, Miley
O'Brien, Andrew Ross Wickman
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (02) : 147 - 150

← 1 2 3 4 5 →